Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

Xenon Pharmaceuticals (Nasdaq:XENE) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 10-13, 2024, in Miami, FL.

Key executives, Ian Mortimer, President and CEO, and Chris Von Seggern, Chief Commercial Officer, will present during a fireside chat on June 12, at 4:00 pm ET. The presentation will be webcast live and available for replay on Xenon's investor relations webpage.

Xenon focuses on developing innovative treatments for neurological and psychiatric disorders, with a product pipeline addressing unmet medical needs such as epilepsy and depression.

Positive

• Participation in a prestigious event like the Goldman Sachs Global Healthcare Conference can increase Xenon's visibility.
• Presentation by key executives indicates confidence in the company's direction and achievements.
• The live webcast and replay availability can enhance investor engagement and transparency.

Negative

• The press release lacks specific new developments or financial data, which could be seen as a missed opportunity to provide more substantive updates.
• No immediate impact or actionable information for shareholders is presented, which may lead to lukewarm reception by investors.

VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in Miami, FL.

Fireside Chat Presentation Details:

Date:	Wednesday, June 12, 2024
Time:	4:00 pm Eastern Time
Webcast:	Register here
Presenters:	Ian Mortimer, President and Chief Executive Officer Chris Von Seggern, Chief Commercial Officer

A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Jodi Regts
Xenon Corporate Affairs
(604) 484-3353
media@xenon-pharma.com

FAQ

When will Xenon Pharmaceuticals present at the Goldman Sachs 45th Annual Global Healthcare Conference?

Xenon Pharmaceuticals will present on June 12, 2024, at 4:00 pm Eastern Time during the Goldman Sachs 45th Annual Global Healthcare Conference.

Who will present on behalf of Xenon Pharmaceuticals at the conference?

Ian Mortimer, President and CEO, and Chris Von Seggern, Chief Commercial Officer, will present on behalf of Xenon Pharmaceuticals.

Where can I watch the Xenon Pharmaceuticals presentation at the conference?

The presentation will be webcast live and available for replay on the investors section of Xenon Pharmaceuticals' website.

What is the focus of Xenon Pharmaceuticals' product pipeline?

Xenon Pharmaceuticals focuses on developing innovative treatments for neurological and psychiatric disorders, including epilepsy and depression.

What is the significance of the Goldman Sachs Global Healthcare Conference for Xenon Pharmaceuticals?

Participation in this prestigious conference can increase Xenon Pharmaceuticals' visibility and engagement with investors and stakeholders.